- Home
- AKBA vs CWBC Comparison
AKBA vs CWBC Comparison
Compare AKBA & CWBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- CWBC
- Stock Information
- Founded
- AKBA 2007
- CWBC 1989
- Country
- AKBA United States
- CWBC United States
- Employees
- AKBA N/A
- CWBC N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- CWBC Major Banks
- Sector
- AKBA Health Care
- CWBC Finance
- Exchange
- AKBA Nasdaq
- CWBC Nasdaq
- Market Cap
- AKBA 336.2M
- CWBC 299.6M
- IPO Year
- AKBA 2014
- CWBC 1996
- Fundamental
- Price
- AKBA $2.14
- CWBC $16.55
- Analyst Decision
- AKBA Strong Buy
- CWBC Buy
- Analyst Count
- AKBA 3
- CWBC 3
- Target Price
- AKBA $6.50
- CWBC $20.67
- AVG Volume (30 Days)
- AKBA 4.5M
- CWBC 45.8K
- Earning Date
- AKBA 05-08-2025
- CWBC 04-21-2025
- Dividend Yield
- AKBA N/A
- CWBC 2.90%
- EPS Growth
- AKBA N/A
- CWBC N/A
- EPS
- AKBA N/A
- CWBC 0.65
- Revenue
- AKBA $160,180,000.00
- CWBC $120,399,000.00
- Revenue This Year
- AKBA $22.50
- CWBC $34.27
- Revenue Next Year
- AKBA $43.23
- CWBC $6.41
- P/E Ratio
- AKBA N/A
- CWBC $25.46
- Revenue Growth
- AKBA N/A
- CWBC 38.79
- 52 Week Low
- AKBA $0.80
- CWBC $15.57
- 52 Week High
- AKBA $2.89
- CWBC $22.89
- Technical
- Relative Strength Index (RSI)
- AKBA 59.49
- CWBC 41.86
- Support Level
- AKBA $1.52
- CWBC $15.80
- Resistance Level
- AKBA $2.16
- CWBC $16.36
- Average True Range (ATR)
- AKBA 0.15
- CWBC 0.83
- MACD
- AKBA 0.04
- CWBC -0.02
- Stochastic Oscillator
- AKBA 96.88
- CWBC 32.89
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About CWBC Community West Bancshares
Community West Bancshares is a bank holding company whose principal business is to serve as the holding company for its wholly-owned subsidiary Community West Bank N.A. Through CWB, the Company provides a variety of financial products and full-service Banking Centers within California's Greater Sacramento, San Joaquin Valley, and Central Coast regions, that provide Commercial Lending, Real Estate, Agribusiness, Private Banking, and Cash Management Departments.